Shots:

• Roche has launched Elecsys SARS-CoV-2 Ag test as an aid in the diagnosis of SARS-CoV-2 infections- in the markets accepting the CE Mark. Additionally- Roche has also filed a EUA to the US FDA
• The test showed 94.5% sensitivity across 200 PCR confirmed symptomatic individuals & 99.9% specificity across 2747 PCR negative symptomatic & screening individuals in clinical studies. The company plans to ramp up production to have a double-digit million number of tests/ month- in early 2021
• The test is an immunoassay intended for the qualitative detection of SARS-CoV-2 present in the respiratory tract including nasopharynx & oropharynx. The test is the latest addition to Roche’s COVID-19 portfolio

 ­ Ref: GlobeNewswire | Image: Roche